Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

Inclusion Criteria: 1. Histologically confirmed diagnosis of adrenocortical carcinoma; 2. Patients with metastatic or inoperable adrenocortical carcinoma that has progressed, metastasized, or recurred after first-line standard treatment (mitotane monotherapy, chemotherapy alone, mitotane combined chemotherapy); 3. Aged \>=18 years; 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 5. At least one measurable lesion, according to RECIST 1.1; 6. Major organ functions within 28 days prior to treatment meet the following criteria(14 days without transfusion): HB≥80g/L, ANC≥1.5x10\^9/L, PLT ≥80x10\^9/L; TBIL≤1.5 ULN, ALT and AST ≤2.5 ULN, if there exists hepatic metastases, ALT and AST ≤5 ULN, Cr ≤1.5 ULN or CCr ≥60ml/min; INR or PT ≤1.5 ULN, APTT ≤1.5 ULN (if the patient is receiving anticoagulant therapy, PT and APTT should be within the expected treatment range); Cardiac Markers and BNP≤ULN；TSH≤ULN (If TSH is abnormal, T3 and T4 should be normal) 7. Appropriate contraception should be used from the start of treatment to 120 days after the end of treatment; 8. Have signed consent form. Exclusion Criteria: 1. Patients with another primary malignancy within 5 years prior to starting the study drug, except for cured in situ cervical carcinoma and cured non-melanoma skin cancer; 2. Have central nervous system metastasis with symptoms and need hormonal intervention; 3. Had received strong CYP3A4 inhibitors within one week prior to enrollment or received strong CYP3A4 inducers within two weeks prior to enrollment; 4. Poor control of high blood pressure (SBP\>140mmHg or DBP\>90mmHg); 5. Congestive heart failure of New York Heart Association (NYHA) Class III or IV; 6. Thromboembolic events occurred within 1 year prior to enrollment; 7. ECG QT interval \>500ms; 8. Previous systemic immunosuppressive therapy; 9. Previous anti-PD-1, anti-PD-L1 antibody or anti- CTLA-4 antibody treatment; 10. Received TKI treatment within 2 weeks prior to starting the study drug; 11. Participate in clinical trials of other interventional drugs within 4 weeks prior to starting the study drug; 12. Received systemic therapy with corticosteroids or other immunosuppressants within 2 weeks prior to starting the study drug; 13. An anti-tumor vaccine or a live vaccine was given within 4 weeks prior to starting the study drug; 14. Major surgery or severe trauma within 4 weeks prior to starting the study drug; 15. Severe infections occurred within 4 weeks prior to starting the study drug; 16. Have an active autoimmune disease or a history of autoimmune diseases; 17. Have a history of immunodeficiency; 18. Have an active tuberculosis infection; 19. Have active hepatitis; 20. Patients with symptoms of gastrointestinal bleeding or risk of bleeding; 21. Active infection, or patients are pregnant or breast-feeding.